Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Am J Physiol Cell Physiol. 2020 Sep 1;319(3):C552-C560. doi: 10.1152/ajpcell.00094.2020. Epub 2020 Jul 22.
A number of cell culture approaches have been described for maintenance of primary hepatocytes. Forming hepatocytes into three-dimensional (3-D) spheroids is one well-accepted method for extending epithelial phenotype of these cells. Our laboratory has previously observed enhanced function of two-dimensional (2-D, monolayer) hepatocyte cultures in microfluidic devices due to increased production of several hepato-inductive growth factors, including hepatocyte growth factor (HGF). In the present study, we wanted to test a hypothesis that culturing hepatocyte spheroids (3-D) in microfluidic devices will also result in enhanced phenotype and function. To test this hypothesis, we fabricated devices with small and large volumes. Both types of devices included a microstructured floor containing arrays of pyramidal wells to promote assembly of hepatocytes into spheroids with individual diameters of ~100 µm. The hepatocyte spheroids were found to be more functional, as evidenced by higher level of albumin synthesis, bile acid production, and hepatic enzyme expression, in low-volume compared with large-volume devices. Importantly, high functionality of spheroid cultures correlated with elevated levels of HGF secretion. Although decay of hepatic function (albumin secretion) was observed over the course 3 wk, this behavior could be abrogated by inhibiting TGF-β1 signaling. With TGF-β1 inhibitor, microfluidic hepatocyte spheroid cultures maintained high and stable levels of albumin synthesis over the course of 4 wk. To further highlight utility of this culture platform for liver disease modeling, we carried out alcohol injury experiments in microfluidic devices and tested protective effects of interleukin-22: a potential therapy for alcoholic hepatitis.
已经有许多细胞培养方法被用于维持原代肝细胞。将肝细胞形成三维(3-D)球体是延长这些细胞上皮表型的一种常用方法。我们实验室之前观察到,由于几种肝诱导生长因子(包括肝细胞生长因子(HGF))的产量增加,二维(2-D,单层)肝细胞培养在微流控装置中的功能增强。在本研究中,我们想要验证一个假设,即培养肝细胞球体(3-D)在微流控装置中也将导致表型和功能增强。为了验证这一假设,我们制造了具有小体积和大体积的设备。这两种类型的设备都包含一个微结构地板,其中包含一系列金字塔形的井,以促进肝细胞组装成直径约为 100 µm 的球体。研究发现,与大体积设备相比,小体积设备中的肝细胞球体功能更强大,表现在白蛋白合成、胆汁酸产生和肝酶表达水平更高。重要的是,球体培养物的高功能与 HGF 分泌水平的升高相关。尽管在 3 周的过程中观察到肝功能(白蛋白分泌)的下降,但通过抑制 TGF-β1 信号可以阻止这种行为。使用 TGF-β1 抑制剂,微流控肝细胞球体培养物在 4 周的过程中保持高且稳定的白蛋白合成水平。为了进一步强调该培养平台在肝脏疾病建模中的应用,我们在微流控装置中进行了酒精损伤实验,并测试了白细胞介素-22 的保护作用:一种治疗酒精性肝炎的潜在疗法。